Trial
NCT05785715
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
AbbVie
Collaborators
—
Condition
Ulcerative Colitis
Intervention
NX-13 250mg
Why stopped
Sponsor Decision\_Not Safety Related
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-15